Brasília – Anvisa approved its Regulatory Agenda for 2026–2027, outlining 155 priority topics that will guide the agency’s rulemaking, revision of existing norms and strategic projects over the next two years. The agenda is organized into thematic axes such as medicines, health products, clinical research, border control, laboratory oversight and transversal regulatory practices. According to the agency, the new cycle reflects contributions from public consultation and aims to strengthen predictability, transparency and alignment with public health needs.

Anvisa emphasized that the agenda is not a list of pre-approved regulations but a strategic roadmap indicating areas where regulatory action is expected or under evaluation. The agency stated that the new cycle reinforces commitments to regulatory coherence, digital transformation, reliance practices and risk-based approaches, supporting both innovation and safety across health-related sectors.

Source: Anvisa